ProCE Banner Activity

CE / CME

Biomarkers in Gastrointestinal Cancer: Applying the Latest Data in Community Practice

Multimedia
Watch this on-demand webcast of a live CCO webinar to gain expert insights on biomarker-driven approaches for treating patients with gastrointestinal cancers.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: April 28, 2022

Expiration: April 27, 2023

No longer available for credit.

Share

Faculty

Pashtoon M. Kasi

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Seagen Inc.

Target Audience

This program is intended for oncologists, surgeons, pathologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with gastrointestinal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with GI malignancies
  • Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients about how the molecular profile will guide therapy decisions and potential need for additional biopsy
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Pashtoon M. Kasi, MD, MS

Director 
Colon Cancer Research 
Weill Cornell Medicine
Director 
Liquid Biopsy Research 
Englander Institute of Precision Medicine 
New York, New Yotk

Pashtoon M. Kasi, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Daiichi Sankyo, Delcath, Eisai, Exact Sciences, Foundation Medicine, Incyte, IPBA, Ipsen (to institution), Lilly, Merck/MSD, Natera, QED, Servier, Taiho (to institution/self), and Tempus and funds for research support (to institution) from Advanced Accelerator Applications, Amgen, Array, AstraZeneca, Bristol-Myers Squibb, BTG/Boston Scientific, RenovoRx, Seagen, and TerSera; and received travel funds from AstraZeneca.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Kay Orbaugh, MSN, NP, AOCNP, has disclosed that she has served as a speaker for AstraZeneca, Bristol-Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-123-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 28, 2022, through April 27, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, confidence, and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.